Sophonix

About Sophonix

Established in July 2017, Sophonix Co., Ltd. is a biotechnology company focused on the in-vitro diagnostics (IVD) market. The company operates from its headquarters in Beijing, China, and maintains dual research and development centers in Beijing and California, USA, to integrate expertise from both regions. Sophonix has demonstrated consistent growth, securing significant funding, including a CNY 100 million Series B round in June 2020 and a later-stage venture round in September 2023. The company's investor base includes notable firms such as Hefei Industry Investment Group, CITIC Medical & Heath Group, and Delian Capital.

Sophonix's business model revolves around the research, development, manufacturing, and sale of medical diagnostic equipment and reagents. The company serves a client base of medical laboratories and healthcare facilities, providing them with tools for more accurate and reliable diagnoses. Its revenue is generated from the sale of these physical products. The company's operations are guided by the slogan, "Popularize the high-quality diagnosis through consistent innovation," which underscores its commitment to making advanced diagnostic tools more accessible.

The product portfolio features a range of analyzers and test kits under its own intellectual property. A key offering is its automatic chemiluminescence immunoassay (CLIA) analyzing systems, such as the Aceso-80-A and MS-Fast series. These systems utilize a magnetic particle CLIA method and single-use cartridges to deliver test results for various conditions, with the Aceso-80-A capable of processing up to 60 tests per hour. In addition to immunoassay analyzers, Sophonix develops pathological diagnosis systems like the Ultra 30 and Ultra 60 automatic immunohistochemical staining machines for medium to large labs. The company has also ventured into molecular diagnostics with the GM-fast-60 system, which employs LAMP technology for the rapid detection of respiratory diseases.